US Patent No: 6,218,506

Number of patents in Portfolio can not be more than 2000

Amyloid .beta. protein (globular assembly and uses thereof)

Stats

ATTORNEY / AGENT: (SPONSORED)
 

Importance

Loading Importance Indicators... loading....

Abstract

The invention described in this disclosure involves a new composition of matter, amyloid beta-derived dementing ligands (ADDL's). ADDLs consist of amyloid .beta. peptide assembled into soluble globular non-fibrillar oligomeric structures that are capable of activating specific cellular processes. The invention further encompasses methods for assaying the formation, presence, receptor protein binding and cellular activities of ADDLs. The invention further encompasses assay methods and inhibitor molecules for cellular signaling molecules activated by ADDLs. Also described are molecules that block proteins that promote the formation of ADDLs.

Loading the Abstract Image... loading....

First Claim

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
NORTHWESTERN UNIVERSITYEVANSTON, IL725
UNIVERSITY OF SOUTHERN CALIFORNIALOS ANGELES, CA865

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Barlow, Ann Evanston, IL 4 64
Chromy, Brett A Evanston, IL 10 114
Finch, Caleb E Altadena, CA 6 108
Klein, William L Lakewood, CA 27 270
Krafft, Grant A Glenview, IL 23 144
Lambert, Mary P Glenview, IL 21 140
Morgan, Todd Kaysville, UT 8 71
Rozovsky, Irina Pasadena, CA 4 64
Wals, Pat Los Angeles, CA 4 64

Cited Art

  • No Cited Art to Display

Patent Citation Ranking

Forward Cites

Patent Info (Count) # Cites Year
 
JANSSEN ALZHEIMER IMMUNOTHERAPY (11)
7,964,192 Prevention and treatment of amyloidgenic disease 1 1999
6,913,745 Passive immunization of Alzheimer's disease 37 2000
7,588,766 Treatment of amyloidogenic disease 8 2000
7,575,880 Method of screening an antibody for activity in clearing an amyloid deposit 8 2000
6,905,686 Active immunization for treatment of alzheimer's disease 32 2000
8,034,339 Prevention and treatment of amyloidogenic disease 0 2004
6,972,127 Prevention and treatment of amyloidogenic disease 35 2004
6,946,135 Prevention and treatment of amyloidogenic disease 27 2004
7,790,856 Humanized antibodies that recognize beta amyloid peptide 1 2006
8,034,348 Prevention and treatment of amyloidogenic disease 0 2007
7,893,214 Humanized antibodies that recognize beta amyloid peptide 0 2007
 
WYETH LLC (9)
7,189,819 Humanized antibodies that recognize beta amyloid peptide 25 2001
7,582,733 Humanized antibodies that recognize beta amyloid peptide 10 2002
7,256,273 Humanized antibodies that recognize beta amyloid peptide 29 2003
7,179,892 Humanized antibodies that recognize beta amyloid peptide 30 2003
7,871,615 Humanized antibodies that recognize beta amyloid peptide 1 2004
7,625,560 Humanized antibodies that recognize beta amyloid peptide 5 2005
7,700,751 Humanized antibodies that recognize β-amyloid peptide 1 2007
8,128,928 Humanized antibodies that recognize beta amyloid peptide 0 2007
8,003,097 Treatment of cerebral amyloid angiopathy 0 2008
 
BIOARCTIC NEUROSCIENCE AB (5)
8,106,164 Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof 1 2005
7,700,719 Arctic β amyloid protofibril 1 2007
8,025,878 Protofibril selective antibodies and the use thereof 1 2007
8,409,575 Antibodies specific for amyloid beta protofibril 0 2011
8,404,459 Antibodies specific for soluble amyloid beta peptide protofibrils and uses thereof 0 2011
 
GENENTECH, INC. (4)
7,892,544 Humanized anti-beta-amyloid antibody 2 2007
8,124,353 Methods of treating and monitoring disease with antibodies 1 2007
8,048,420 Monoclonal antibody 1 2008
8,246,954 Methods of treating amyloidosis with humanized anti-beta-amyloid antibodies 0 2009
 
NORTHWESTERN UNIVERSITY (4)
7,811,563 Anti-addl antibodies and uses thereof 0 2005
7,780,963 Anti-ADDL antibodies and uses thereof 0 2005
8,128,930 Anti-ADDL antibodies and uses thereof 0 2010
8,383,113 Anti-ADDL antibodies and uses thereof 0 2012
 
MERCK SHARP & DOHME CORP. (3)
7,731,962 Anti-ADDL monoclonal antibody and use thereof 0 2006
8,105,593 Anti-ADDL monoclonal antibody and use thereof 0 2010
8,420,093 Anti-ADDL monoclonal antibody and use thereof 0 2012
 
WASHINGTON UNIVERSITY (3)
7,771,722 Assay method for alzheimer's disease 0 2002
7,195,761 Humanized antibodies that sequester abeta peptide 22 2002
7,892,545 Humanized antibodies that sequester amyloid beta peptide 0 2008
 
APPLIED MOLECULAR EVOLUTION, INC. (2)
7,575,747 Aβ binding molecules 1 2004
8,105,597 Aβ binding molecules 0 2009
 
KYOWA HAKKO KIRIN CO., LTD. (2)
8,333,967 Anti-Aβ oligomer humanized antibody 0 2010
8,303,954 Anti-Aβ oligomer humanized antibody 0 2010
 
ABBOTT LABORATORIES (1)
7,902,328 Amyloid β(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof 0 2004
 
ABBVIE INC. (1)
8,263,558 Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins 0 2006
 
AC IMMUNE SA (1)
7,772,375 Monoclonal antibodies that recognize epitopes of amyloid-beta 4 2006
 
CORNELL RESEARCH FOUNDATION, INC. (1)
6,815,175 Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder 10 2002
 
ELI LILLY AND COMPANY (1)
8,066,999 PEGylated Aβ fab 0 2008
 
IMMUNAS PHARMA, INC. (1)
8,378,081 Antibodies that specifically bind to Aβ oligomers and uses thereof 0 2009
 
UNIVERSITY OF SOUTHERN CALIFORNIA (1)
7,638,283 Amyloid β protein (globular assembly and uses thereof) 1 2005